Haussier
Johnson & Johnson's stock remains near record highs following strong Q2 2026 earnings.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Johnson & Johnson's stock is trading close to its 52-week high, supported by robust Q2 2026 earnings and an optimistic full-year outlook. The company reported a 6.6% increase in revenue to $25.3 billion and raised its 2026 sales guidance to $101.1 billion, with adjusted earnings per share projected at $11.68. Additionally, the stock's valuation remains attractive, trading at approximately 22.3 times projected earnings for 2026.
Points clés
- Q2 2026 earnings exceeded expectations, with revenue up 6.6% year-over-year to $25.3 billion and adjusted EPS of $2.90, surpassing the consensus estimate of $2.85.
- The company raised its full-year 2026 sales guidance to $101.1 billion and adjusted EPS to $11.68, indicating strong financial health.
- The stock is trading near its 52-week high, with a market capitalization of $658.24 billion as of August 25, 2026.
- The stock's valuation is approximately 22.3 times projected earnings for 2026, suggesting a premium multiple for the company's diversified healthcare portfolio.
Sources
- Johnson & Johnson stock holds close to record highs as Q2 2026 earnings and guidance support valuationAD HOC NEWS · August 20, 2026
- Johnson & Johnson stock trades near a 52-week high after Q2 beatAD HOC NEWS · August 26, 2026
- Johnson & Johnson's stock price at critical turning pointMarketBeat · January 24, 2024
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
